高效裂解的 HIV-1 包膜:它们对疫苗免疫原的开发重要吗?

Q2 Medicine
Therapeutic Advances in Vaccines and Immunotherapy Pub Date : 2020-10-08 eCollection Date: 2020-01-01 DOI:10.1177/2515135520957763
Supratik Das, Rajesh Kumar, Shubbir Ahmed, Hilal Ahmad Parray, Sweety Samal
{"title":"高效裂解的 HIV-1 包膜:它们对疫苗免疫原的开发重要吗?","authors":"Supratik Das, Rajesh Kumar, Shubbir Ahmed, Hilal Ahmad Parray, Sweety Samal","doi":"10.1177/2515135520957763","DOIUrl":null,"url":null,"abstract":"<p><p>The enormous diversity of HIV-1 is a significant impediment in selecting envelopes (Envs) that can be suitable for designing vaccine immunogens. While tremendous progress has been made in developing soluble, trimeric, native-like Env proteins, those that have elicited neutralizing antibodies (Abs) in animal models are relatively few. A strategy of selecting naturally occurring Envs suitable for immunogen design by studying the correlation between efficient cleavage on the cell surface and their selective binding to broadly neutralizing Abs (bNAbs) and not to non-neutralizing Abs (non-NAbs), properties essential in immunogens, may be useful. Here we discuss some of the challenges of developing an efficacious HIV-1 vaccine and the work done in generating soluble immunogens. We also discuss the study of naturally occurring, membrane-bound, efficiently cleaved (naturally more sensitive to furin) Envs and how they may positively add to the repertoire of HIV-1 Envs that can be used for vaccine immunogen design. However, even with such Envs, the challenges of developing well-folded, native-like trimers as soluble proteins or using other immunogen strategies such as virus-like particles with desirable antigenic properties remain, and are formidable. In spite of the progress that has been made in the HIV-1 vaccine field, an immunogen that elicits neutralizing Abs with significant breadth and potency in vaccines has still not been developed. Efficiently cleaved Envs may increase the number of available Envs suitable for immunogen design and should be studied further.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/dd/10.1177_2515135520957763.PMC7549152.pdf","citationCount":"0","resultStr":"{\"title\":\"Efficiently cleaved HIV-1 envelopes: can they be important for vaccine immunogen development?\",\"authors\":\"Supratik Das, Rajesh Kumar, Shubbir Ahmed, Hilal Ahmad Parray, Sweety Samal\",\"doi\":\"10.1177/2515135520957763\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The enormous diversity of HIV-1 is a significant impediment in selecting envelopes (Envs) that can be suitable for designing vaccine immunogens. While tremendous progress has been made in developing soluble, trimeric, native-like Env proteins, those that have elicited neutralizing antibodies (Abs) in animal models are relatively few. A strategy of selecting naturally occurring Envs suitable for immunogen design by studying the correlation between efficient cleavage on the cell surface and their selective binding to broadly neutralizing Abs (bNAbs) and not to non-neutralizing Abs (non-NAbs), properties essential in immunogens, may be useful. Here we discuss some of the challenges of developing an efficacious HIV-1 vaccine and the work done in generating soluble immunogens. We also discuss the study of naturally occurring, membrane-bound, efficiently cleaved (naturally more sensitive to furin) Envs and how they may positively add to the repertoire of HIV-1 Envs that can be used for vaccine immunogen design. However, even with such Envs, the challenges of developing well-folded, native-like trimers as soluble proteins or using other immunogen strategies such as virus-like particles with desirable antigenic properties remain, and are formidable. In spite of the progress that has been made in the HIV-1 vaccine field, an immunogen that elicits neutralizing Abs with significant breadth and potency in vaccines has still not been developed. Efficiently cleaved Envs may increase the number of available Envs suitable for immunogen design and should be studied further.</p>\",\"PeriodicalId\":33285,\"journal\":{\"name\":\"Therapeutic Advances in Vaccines and Immunotherapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/dd/10.1177_2515135520957763.PMC7549152.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Vaccines and Immunotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/2515135520957763\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Vaccines and Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2515135520957763","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

HIV-1 的巨大多样性严重阻碍了选择适合设计疫苗免疫原的包膜(Envs)。虽然在开发可溶性、三聚体、类原生 Env 蛋白方面取得了巨大进展,但能在动物模型中激发中和抗体(Abs)的 Env 蛋白却相对较少。通过研究细胞表面的高效裂解与其选择性结合广谱中和抗体(bNAbs)而非非中和抗体(non-NAbs)之间的相关性(这些特性对免疫原至关重要),选择适合免疫原设计的天然Envs的策略可能是有用的。在此,我们将讨论开发有效的 HIV-1 疫苗所面临的一些挑战,以及在生成可溶性免疫原方面所做的工作。我们还讨论了对天然存在、膜结合、高效裂解(天然对呋喃更敏感)的 Envs 的研究,以及这些 Envs 如何积极地增加可用于疫苗免疫原设计的 HIV-1 Envs 种类。然而,即使有了这样的 Envs,要开发折叠良好、类似于本地三聚体的可溶性蛋白,或使用其他免疫原策略(如具有理想抗原特性的类病毒颗粒),仍然面临艰巨的挑战。尽管 HIV-1 疫苗领域已经取得了进展,但仍未开发出一种能在疫苗中诱发具有显著广泛性和效力的中和抗体的免疫原。高效裂解的 Envs 可能会增加适用于免疫原设计的可用 Envs 的数量,因此应进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Efficiently cleaved HIV-1 envelopes: can they be important for vaccine immunogen development?

Efficiently cleaved HIV-1 envelopes: can they be important for vaccine immunogen development?

Efficiently cleaved HIV-1 envelopes: can they be important for vaccine immunogen development?

Efficiently cleaved HIV-1 envelopes: can they be important for vaccine immunogen development?

The enormous diversity of HIV-1 is a significant impediment in selecting envelopes (Envs) that can be suitable for designing vaccine immunogens. While tremendous progress has been made in developing soluble, trimeric, native-like Env proteins, those that have elicited neutralizing antibodies (Abs) in animal models are relatively few. A strategy of selecting naturally occurring Envs suitable for immunogen design by studying the correlation between efficient cleavage on the cell surface and their selective binding to broadly neutralizing Abs (bNAbs) and not to non-neutralizing Abs (non-NAbs), properties essential in immunogens, may be useful. Here we discuss some of the challenges of developing an efficacious HIV-1 vaccine and the work done in generating soluble immunogens. We also discuss the study of naturally occurring, membrane-bound, efficiently cleaved (naturally more sensitive to furin) Envs and how they may positively add to the repertoire of HIV-1 Envs that can be used for vaccine immunogen design. However, even with such Envs, the challenges of developing well-folded, native-like trimers as soluble proteins or using other immunogen strategies such as virus-like particles with desirable antigenic properties remain, and are formidable. In spite of the progress that has been made in the HIV-1 vaccine field, an immunogen that elicits neutralizing Abs with significant breadth and potency in vaccines has still not been developed. Efficiently cleaved Envs may increase the number of available Envs suitable for immunogen design and should be studied further.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Therapeutic Advances in Vaccines and Immunotherapy
Therapeutic Advances in Vaccines and Immunotherapy Medicine-Pharmacology (medical)
CiteScore
5.10
自引率
0.00%
发文量
15
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信